U.S. markets open in 44 minutes
  • S&P Futures

    -32.50 (-0.78%)
  • Dow Futures

    -197.00 (-0.58%)
  • Nasdaq Futures

    -130.00 (-1.03%)
  • Russell 2000 Futures

    -18.20 (-0.91%)
  • Crude Oil

    +0.91 (+1.24%)
  • Gold

    +8.90 (+0.47%)
  • Silver

    -0.02 (-0.09%)

    -0.0028 (-0.26%)
  • 10-Yr Bond

    +0.0910 (+2.58%)
  • Vix

    +0.79 (+4.22%)

    +0.0002 (+0.02%)

    +1.2900 (+0.98%)

    -342.14 (-1.47%)
  • CMC Crypto 200

    -11.55 (-2.15%)
  • FTSE 100

    -57.08 (-0.72%)
  • Nikkei 225

    +184.19 (+0.67%)

Insider Buying: The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Independent Director Just Bought 38% More Shares

Whilst it may not be a huge deal, we thought it was good to see that the DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Independent Director, R. Giuffre, recently bought US$80k worth of stock, for US$1.20 per share. That purchase might not be huge but it did increase their holding by 38%.

View our latest analysis for DiaMedica Therapeutics

The Last 12 Months Of Insider Transactions At DiaMedica Therapeutics

Over the last year, we can see that the biggest insider purchase was by insider Thomas von Koch for US$400k worth of shares, at about US$1.36 per share. That means that an insider was happy to buy shares at around the current price of US$1.48. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. In this case we're pleased to report that the insider purchases were made at close to current prices.

While DiaMedica Therapeutics insiders bought shares during the last year, they didn't sell. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!


There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Insider Ownership

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. It appears that DiaMedica Therapeutics insiders own 34% of the company, worth about US$13m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

What Might The Insider Transactions At DiaMedica Therapeutics Tell Us?

It is good to see recent purchasing. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. When combined with notable insider ownership, these factors suggest DiaMedica Therapeutics insiders are well aligned, and that they may think the share price is too low. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. To that end, you should learn about the 3 warning signs we've spotted with DiaMedica Therapeutics (including 1 which is a bit unpleasant).

Of course DiaMedica Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here